The Medicines Company Rises On Novartis Takeover Rumors
As Inclisiran Cuts Bad Cholesterol Levels In Half
It's been a good week for the US company with its PCSK9 gene-silencing drug impressing at the American Heart Association meeting and reports that Novartis is close to making a bid.
